News

ascopubs.org10y
A multi-center phase II open-label study (CheckMate 204) to evaluate safety and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI) followed by NIVO monotherapy ...
In these pts, progressive brain disease is the major cause of tumor-related death (median overall survival [OS] after diagnosis, 4 months). NIVO (a fully human IgG4 PD-1 immune checkpoint inhibitor ...